CoChat
Sign Up
Cited by 685Cancer Immunotherapy and BiomarkersMicroRNA in disease regulationCancer-related Molecular Pathways

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

PDL1 Regulation by p53 via miR-34

Open access
Cortez, Maria Angelica, Ivan, Cristina, Valdecanas, David, Wang, Xiaohong, Peltier, Heidi J., Ye, Yuping, Araujo, Luiz, Carbone, David P., Shilo, Konstantin, Giri, Dipak K, Kelnar, Kevin, Martin, Desiree, Komaki, Ritsuko, Gomez, Daniel R., Krishnan, Sunil, Calin, George A., Bader, Andreas G., Welsh, James W.·2016·JNCI: Journal of the National Cancer Institute
DOI 10.1093/jnci/djv303PMC PMC4862407
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: Although clinical studies have shown promise for targeting PD1/PDL1 signaling in non-small cell lung cancer (NSCLC), the regulation of PDL1 expression is poorly understood. Here, we show that PDL1 is regulated by p53 via miR-34. METHODS: p53 wild-type and p53-deficient cell lines (p53(-/-) and p53(+/+) HCT116, p53-inducible H1299, and p53-knockdown H460) were used to determine if p53 regulates PDL1 via miR-34. PDL1 and miR-34a expression were analyzed in samples from patients with NSCLC and mutated p53 vs wild-type p53 tumors from The Cancer Genome Atlas for Lung Adenocarcinoma (TCGA LUAD). We confirmed that PDL1 is a direct target of miR-34 with western blotting and luciferase assays and used a p53(R172HΔ)g/+K-ras(LA1/+) syngeneic mouse model (n = 12) to deliver miR-34a-loaded liposomes (MRX34) plus radiotherapy (XRT) and assessed PDL1 expression and tumor-infiltrating lymphocytes (TILs). A two-sided t test was applied to compare the mean between different treatments. RESULTS: We found that p53 regulates PDL1 via miR-34, which directly binds to the PDL1 3' untranslated region in models of NSCLC (fold-change luciferase activity to control group, mean for miR-34a = 0.50, SD = 0.2, P < .001; mean for miR-34b = 0.52, SD = 0.2, P = .006; and mean for miR-34c = 0.59, SD = 0.14, and P = .006). Therapeutic delivery of MRX34, currently the subject of a phase I clinical trial, promoted TILs (mean of CD8 expression percentage of control group = 22.5%, SD = 1.9%; mean of CD8 expression percentage of MRX34 = 30.1%, SD = 3.7%, P = .016, n = 4) and reduced CD8(+)PD1(+) cells in vivo (mean of CD8/PD1 expression percentage of control group = 40.2%, SD = 6.2%; mean of CD8/PD1 expression percentage of MRX34 = 20.3%, SD = 5.1%, P = .001, n = 4). Further, MRX34 plus XRT increased CD8(+) cell numbers more than either therapy alone (mean of CD8 expression percentage of MRX34 plus XRT to control group = 44.2%, SD = 8.7%, P = .004, n = 4). Finally, miR-34a delivery reduced the numbers of radiation-induced macrophages (mean of F4-80 expression percentage of control group = 52.4%, SD = 1.7%; mean of F4-80 expression percentage of MRX34 = 40.1%, SD = 3.5%, P = .008, n = 4) and T-regulatory cells. CONCLUSIONS: We identified a novel mechanism by which tumor immune evasion is regulated by p53/miR-34/PDL1 axis. Our results suggest that delivery of miRNAs with standard therapies, such as XRT, may represent a novel therapeutic approach for lung cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/jnci/djv303

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. p53 regulation of PDL1 via miR-34. A) miR-34a, miR-34b, and miR-34c are upregulated in HCT116 p53+/+ cells treated with nutlin 3 (10 µM for 24 hours) (P = .0001, P < .001, P < .001) and in (C) H1299 p53-inducible cells treated with ponasterone A (PoA) (5 µM for 24, 48, and 72 hours) compared with their respective controls, confirming that p53 overexpression induces miR-34a, miR-34b, and perhaps miR-34c expression (P = .001, P = .004, P = .09). An unpaired t test was used to calculate the two-sided P values. E) Downregulation of miR-34a but not miR-34b or miR-34c, in H460 cells expressing p53-targeting shRNA compared with control (P = .006, P = .19, P = .20). An unpaired t test was used to calculate the two-sided P values. B) Downregulation of PDL1 expression in HCT116 p53+/+ vs p53-/- cells and in H1299 p53-inducible cells (D) and upregulation of PDL1 in H460 cells treated with p53-shRNA (F). G) Immunohistochemical staining of samples from patients with NSCLC showing higher PDL1 protein levels (top row) in tumors with p53 mutation than in tumors with wild-type (wt) p53 (3 patients per group). Chromogenic in situ hybridization staining (CISH; bottom row) indicated downregulation of miR-34a in tumors with mutated p53 relative to tumors with wt p53. Magnification ×100. Scale bar = 100 μm. Error bars on the bar charts represent standard deviation. *P < .05, **P < .01, ***P < .001. ctrl = control; mut = mutated; PoA = ponasterone A; wt = wild-type.
Figure 1. p53 regulation of PDL1 via miR-34. A) miR-34a, miR-34b, and miR-34c are upregulated in HCT116 p53+/+ cells treated with nutlin 3 (10 µM for 24 hours) (P = .0001, P < .001, P < .001) and in (C) H1299 p53-inducible cells treated with ponasterone A (PoA) (5 µM for 24, 48, and 72 hours) compared with their respective controls, confirming that p53 overexpression induces miR-34a, miR-34b, and perhaps miR-34c expression (P = .001, P = .004, P = .09). An unpaired t test was used to calculate the two-sided P values. E) Downregulation of miR-34a but not miR-34b or miR-34c, in H460 cells expressing p53-targeting shRNA compared with control (P = .006, P = .19, P = .20). An unpaired t test was used to calculate the two-sided P values. B) Downregulation of PDL1 expression in HCT116 p53+/+ vs p53-/- cells and in H1299 p53-inducible cells (D) and upregulation of PDL1 in H460 cells treated with p53-shRNA (F). G) Immunohistochemical staining of samples from patients with NSCLC showing higher PDL1 protein levels (top row) in tumors with p53 mutation than in tumors with wild-type (wt) p53 (3 patients per group). Chromogenic in situ hybridization staining (CISH; bottom row) indicated downregulation of miR-34a in tumors with mutated p53 relative to tumors with wt p53. Magnification ×100. Scale bar = 100 μm. Error bars on the bar charts represent standard deviation. *P < .05, **P < .01, ***P < .001. ctrl = control; mut = mutated; PoA = ponasterone A; wt = wild-type.CC BY · PubMed Central
Figure 2. Correlation of p53 with PDL1 expression in patients with non–small cell lung cancer. A) Correlation between p53 and PDL1 (CD274) mRNA expression in samples from 181 patients with NSCLC from The Cancer Genome Atlas (TCGA) (P < .001) (29). The Spearman’s rank-order correlation test was applied to measure the strength of the association between p53 and PDL1 (CD274) mRNA levels. B) PDL1 expression in patients with p53-mutated tumors (n = 84) and p53 wild-type (wt) tumors (n = 97) showed that tumors with mutated p53 had higher PDL1 levels than did those with wt p53 (P = .03). CD274 levels were compared between p53 mutant tumors and p53 wt tumors with Mann-Whitney tests. C) miR-34a levels were lower in tumors with mutated p53 vs wt p53 (P = .01). A box-and-whisker plot is used to represent the data. Box plot represents first (lower bound) quartile, median and third (upper bound) quartile. Whiskers, representing 1.5 times the interquartile range, were used to visualize data (log2) for these comparisons. Mann-Whitney-Wilcoxon test. Two-sided. D) Kaplan-Meier overall survival curves according to CD274 and TP53 expression in TCGA LUAD patients cohorts. The number of patients at risk in high CD274/low TP53 and low CD274/high TP53 groups at different time points are presented at the bottom of the graph. Log-rank test, two-sided. Patients with tumors that expressed high PDL1 and low p53 levels had lower survival rates than did patients with low PDL1/high p53 tumors (P = .005). E and F) Patients with high miR-34a/high p53 or high p53-only tumors had better survival rates than did patients with low miR-34a/low p53 tumors (E) (P = .004) or low p53-only tumors (F) (P = .03). The log-rank test was used to determine the association between mRNA/miRNA expression and overall survival, and the Kaplan-Meyer method was used to generate survival curves. All tests were two-sided and considered statistically significant at the .05 level. *P < .05, **P < .01, ***P < .001. LUAD = lung adenocarcinoma; TCGA = The Cancer Genome Atlas; WT = wild-type.
Figure 2. Correlation of p53 with PDL1 expression in patients with non–small cell lung cancer. A) Correlation between p53 and PDL1 (CD274) mRNA expression in samples from 181 patients with NSCLC from The Cancer Genome Atlas (TCGA) (P < .001) (29). The Spearman’s rank-order correlation test was applied to measure the strength of the association between p53 and PDL1 (CD274) mRNA levels. B) PDL1 expression in patients with p53-mutated tumors (n = 84) and p53 wild-type (wt) tumors (n = 97) showed that tumors with mutated p53 had higher PDL1 levels than did those with wt p53 (P = .03). CD274 levels were compared between p53 mutant tumors and p53 wt tumors with Mann-Whitney tests. C) miR-34a levels were lower in tumors with mutated p53 vs wt p53 (P = .01). A box-and-whisker plot is used to represent the data. Box plot represents first (lower bound) quartile, median and third (upper bound) quartile. Whiskers, representing 1.5 times the interquartile range, were used to visualize data (log2) for these comparisons. Mann-Whitney-Wilcoxon test. Two-sided. D) Kaplan-Meier overall survival curves according to CD274 and TP53 expression in TCGA LUAD patients cohorts. The number of patients at risk in high CD274/low TP53 and low CD274/high TP53 groups at different time points are presented at the bottom of the graph. Log-rank test, two-sided. Patients with tumors that expressed high PDL1 and low p53 levels had lower survival rates than did patients with low PDL1/high p53 tumors (P = .005). E and F) Patients with high miR-34a/high p53 or high p53-only tumors had better survival rates than did patients with low miR-34a/low p53 tumors (E) (P = .004) or low p53-only tumors (F) (P = .03). The log-rank test was used to determine the association between mRNA/miRNA expression and overall survival, and the Kaplan-Meyer method was used to generate survival curves. All tests were two-sided and considered statistically significant at the .05 level. *P < .05, **P < .01, ***P < .001. LUAD = lung adenocarcinoma; TCGA = The Cancer Genome Atlas; WT = wild-type.CC BY · PubMed Central
Figure 3. miR-34s regulation of PDL1. Endogenous levels of miR-34a, -b, and -c in non–small cell lung cancer (NSCLC) cell lines. A) PDL1 expression in A549, H460, and H1299 cells transfected with miR-34a, -b, and -c. B-J) NSCLC cell lines were treated with miR-34a, miR-34b, or miR-34c at 100nM, and 24 hours later RNA was isolated to study miR-34a, -b, and -c transfection efficiency. At 96 hours after transfection, cell lysates were collected for protein analysis. Quantification of western blots shows that forced overexpression of miR-34a, miR-34b, or miR-34c suppressed PDL1 protein expression compared with a scrambled control. K) Luciferase activity in cells cotransfected with miR-34a, -b, or -c or a scrambled control and a luciferase reporter construct encoding the luciferase gene fused either to the wild-type PDL1 3’ UTR (PDL1 wt) or a mutated PDL1 3’ UTR (PDL1 mut). All three of the miR-34s reduced luciferase activity (P < .001, P =.006, and P =.006). An unpaired t test was used to calculate the two-sided P values. *P < .05, **P < .01, ***P < .001. Error bars on the bar charts represent standard deviation. Similar results were observed in three replicates. mut = mutated; NSCLC = non–small cell lung cancer; scr = scrambled; wt = wild-type.
Figure 3. miR-34s regulation of PDL1. Endogenous levels of miR-34a, -b, and -c in non–small cell lung cancer (NSCLC) cell lines. A) PDL1 expression in A549, H460, and H1299 cells transfected with miR-34a, -b, and -c. B-J) NSCLC cell lines were treated with miR-34a, miR-34b, or miR-34c at 100nM, and 24 hours later RNA was isolated to study miR-34a, -b, and -c transfection efficiency. At 96 hours after transfection, cell lysates were collected for protein analysis. Quantification of western blots shows that forced overexpression of miR-34a, miR-34b, or miR-34c suppressed PDL1 protein expression compared with a scrambled control. K) Luciferase activity in cells cotransfected with miR-34a, -b, or -c or a scrambled control and a luciferase reporter construct encoding the luciferase gene fused either to the wild-type PDL1 3’ UTR (PDL1 wt) or a mutated PDL1 3’ UTR (PDL1 mut). All three of the miR-34s reduced luciferase activity (P < .001, P =.006, and P =.006). An unpaired t test was used to calculate the two-sided P values. *P < .05, **P < .01, ***P < .001. Error bars on the bar charts represent standard deviation. Similar results were observed in three replicates. mut = mutated; NSCLC = non–small cell lung cancer; scr = scrambled; wt = wild-type.CC BY · PubMed Central
Figure 4. PDL1 expression after in vivo delivery of miR-34a. Analysis of miR-34a and PDL1 expression levels in subcutaneous 344SQ tumors treated with MRX34 (n = 2) by quantitative polymerase chain reaction (A), by western blotting (C), by flow cytometry (B) (P = .04, n = 2; an unpaired t test was used to calculate the two-sided P value) (D), or by immunohistochemical staining (E) in a syngeneic mouse model. Scale bar = 200 μm. F) MRX34-induced downregulation of PDL1 in an H1299 xenograft model described elsewhere (37). Magnification ×100. Scale bar = 100 μm. *P < .05. Error bars on the bar charts represent standard deviation. ctrl = control; IHC = immunohistochemistry; MRX34 = miR-34a–loaded liposomes.
Figure 4. PDL1 expression after in vivo delivery of miR-34a. Analysis of miR-34a and PDL1 expression levels in subcutaneous 344SQ tumors treated with MRX34 (n = 2) by quantitative polymerase chain reaction (A), by western blotting (C), by flow cytometry (B) (P = .04, n = 2; an unpaired t test was used to calculate the two-sided P value) (D), or by immunohistochemical staining (E) in a syngeneic mouse model. Scale bar = 200 μm. F) MRX34-induced downregulation of PDL1 in an H1299 xenograft model described elsewhere (37). Magnification ×100. Scale bar = 100 μm. *P < .05. Error bars on the bar charts represent standard deviation. ctrl = control; IHC = immunohistochemistry; MRX34 = miR-34a–loaded liposomes.CC BY · PubMed Central
Figure 5. Impact of therapeutic miR-34a delivery combined with radiotherapy on immune cell populations in the tumor microenvironment. Subcutaneous tumors were created by inoculating 1 x 106 344SQ cells derived from a spontaneous subcutaneous lung metastasis from a p53R172HΔg/+K-rasLA1/+ mouse (25) into the right leg of each syngeneic 129Sv/Ev mouse. One week after tumor implantation, mice were randomly assigned to one of four groups: control, MRX34 only, radiation (XRT), or MRX34 plus XRT. The MRX formulation was given as subcutaneous injections at a dose of 1mg/kg (total of 8 injections), and local irradiation was given in 6-Gy fractions to a total dose of 18 Gy over three days, starting when the tumors were 8mm in diameter. For the combination-therapy condition, MRX34 was given one hour before XRT. A) One week after treatment completion, flow cytometry revealed that MRX34 + XRT increased the number of CD8+ cells compared with control or either treatment given alone (P = .004, n = 4). B and C) MRX34 reduced the numbers of PD1+ T-cells (B) and macrophages (C) (P = .001 and P = .008, n = 4). MRX34+XRT combination treatment was more effective in reducing the numbers of PD1+ T-cells (P = .02, n = 4) and macrophages than was XRT alone. (d) XRT seemed to increase the numbers of T-regulatory cells (Tregs) over the control condition, but none of the treatments showed statistically significant effects on Tregs. E) Interferon-gamma levels were increased by MRX34 only and by MRX34 + XRT vs control or XRT alone; MRX34 + XRT increased levels of tumor necrosis factor–alpha. An unpaired t test was used to calculate the two-sided P values. F) MRX34 + XRT delayed tumor growth compared with the control condition in a 344SQ mouse model (n = 6). *P < .05. Error bars on the bar charts represent standard deviation. IFNγ = interferon-gamma; MRX34 = miR-34a–loaded liposomes; TNFα = tumor necrosis factor–alpha; XRT = radiotherapy.
Figure 5. Impact of therapeutic miR-34a delivery combined with radiotherapy on immune cell populations in the tumor microenvironment. Subcutaneous tumors were created by inoculating 1 x 106 344SQ cells derived from a spontaneous subcutaneous lung metastasis from a p53R172HΔg/+K-rasLA1/+ mouse (25) into the right leg of each syngeneic 129Sv/Ev mouse. One week after tumor implantation, mice were randomly assigned to one of four groups: control, MRX34 only, radiation (XRT), or MRX34 plus XRT. The MRX formulation was given as subcutaneous injections at a dose of 1mg/kg (total of 8 injections), and local irradiation was given in 6-Gy fractions to a total dose of 18 Gy over three days, starting when the tumors were 8mm in diameter. For the combination-therapy condition, MRX34 was given one hour before XRT. A) One week after treatment completion, flow cytometry revealed that MRX34 + XRT increased the number of CD8+ cells compared with control or either treatment given alone (P = .004, n = 4). B and C) MRX34 reduced the numbers of PD1+ T-cells (B) and macrophages (C) (P = .001 and P = .008, n = 4). MRX34+XRT combination treatment was more effective in reducing the numbers of PD1+ T-cells (P = .02, n = 4) and macrophages than was XRT alone. (d) XRT seemed to increase the numbers of T-regulatory cells (Tregs) over the control condition, but none of the treatments showed statistically significant effects on Tregs. E) Interferon-gamma levels were increased by MRX34 only and by MRX34 + XRT vs control or XRT alone; MRX34 + XRT increased levels of tumor necrosis factor–alpha. An unpaired t test was used to calculate the two-sided P values. F) MRX34 + XRT delayed tumor growth compared with the control condition in a 344SQ mouse model (n = 6). *P < .05. Error bars on the bar charts represent standard deviation. IFNγ = interferon-gamma; MRX34 = miR-34a–loaded liposomes; TNFα = tumor necrosis factor–alpha; XRT = radiotherapy.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Research works printed but not linked: 1

  1. 1998, Requirement for p53 and p21 to sustain G2 arrest after DNA damage, Science, 282, 1497

Cited by

Sorted by citations

Items 501–600 of 685

Related

See all

Metadata

Authors
Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., Kelnar, K., Martin, D., Komaki, R., Gomez, D. R., Krishnan, S., Calin, G. A., Bader, A. G., & Welsh, J. W.
Affiliations
The University of Texas MD Anderson Cancer Center (US)
Corresponding author
Welsh, James W.
ORCID
Venue
JNCI: Journal of the National Cancer Institute
Publisher
Oxford University Press (OUP)
Published
2015-11-17
Volume
108
Issue
1
ISSN
  • 0027-8874 (ISSN-L)
  • 1460-2105
DOI
10.1093/jnci/djv303
PMC
PMC4862407
OpenAlex
W2173135538
Cited by
683
References
57
Citations by year
2026: 42 · 2025: 53 · 2024: 72 · 2023: 66 · 2022: 72 · 2021: 94 · 2020: 86 · 2019: 61 · 2018: 62 · 2017: 50 · 2016: 24
FWCI
19.80
Type
journal article
Language
en
Open access
Locations
  • JNCI Journal of the National Cancer Institute (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • U.S. Department of Defense (W81XWH0610303, W81XWH, W81XWH-07-1-03060)
  • Cancer Prevention and Research Institute of Texas (CA016672)
  • Doctors Cancer Foundation
  • Lung Cancer Research Foundation
  • National Institutes of Health (UH2TR000943, W81XWH, CA- 016672, 1UH2TR00943-01)
  • University of Texas MD Anderson Cancer Center ((CA016672), grant CA016672)
  • National Cancer Institute (Grant CA016672, CA 016672, CA016672 to, 1UH2TR00943-01, R01CA182905, P30CA016672)
  • National Center for Advancing Translational Sciences (1UH2TR00943-01)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Keywords
PD-L1, p53, miR-34, non-small cell lung cancer, lung adenocarcinoma, miR-34a, miR-34b, miR-34c, 3' untranslated region, tumor-infiltrating lymphocytes, radiotherapy, immune checkpoint, TP53 mutation
MeSH terms
Adenocarcinoma of Lung, Adenocarcinoma, Animals, Carcinoma, Non-Small-Cell Lung, Liposomes, Lung Neoplasms, Neoplasms, Experimental, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, CD8 Antigens, MicroRNAs, Cell Line, Tumor, Cell Proliferation, Mice, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review